GW-501516

GW-501516 is a PPARδ agonist with a molecular weight of 453.49 Da and the molecular formula C21H18F3NO3S2. It was developed through a collaboration between GlaxoSmithKline and Ligand Pharmaceuticals in the late 1990s and early 2000s as part of a broad effort to identify small molecules capable of treating metabolic syndrome, dyslipidemia, and cardiovascular disease. The compound attracted attention because PPARδ, unlike its better-known relatives PPARα and PPARγ, appeared to govern fat-burning programs in skeletal muscle — a tissue responsible for a large share of the body's total energy expenditure.

Early preclinical work showed that GW-501516 could raise levels of high-density lipoprotein (HDL) cholesterol, lower triglycerides, and improve insulin sensitivity in animal models, making it an appealing candidate for treating conditions like obesity and type 2 diabetes. A 2006 review published in Current Opinion in Investigational Drugs described the compound's cardiovascular research profile and noted its potential across metabolic indications. The same period saw parallel investigation into its effects on lipoproteins, summarized in a 2007 American Journal of Cardiology supplement focused on PPARδ and lipid biology.

Researchers also began examining GW-501516 beyond metabolism. Studies published in the Journal of Neuroinflammation (2009) and the Journal of Neuroscience (2010) explored whether PPARδ activation could reduce inflammation in the brain or protect cerebrovascular tissue after ischemic injury, suggesting the compound had biological reach beyond muscle and fat.

Development was halted when toxicology studies in multiple animal species revealed that GW-501516 dramatically accelerated the growth of pre-existing cancerous and pre-cancerous lesions across a range of tissues. This finding led GlaxoSmithKline to discontinue the program entirely before the compound advanced to meaningful human clinical trials. Despite this, GW-501516 gained a second life in athletic and fitness communities, where it is marketed for endurance enhancement — a use that occurs entirely outside of supervised research contexts and without a credible human safety dataset.

GW-501516 acts as a high-affinity, selective agonist of peroxisome proliferator-activated receptor delta (PPARδ), also referred to in some literature as PPARβ/δ. PPARδ is a ligand-activated nuclear receptor expressed at high levels in skeletal muscle, cardiac muscle, adipose tissue, and the brain. When GW-501516 binds to PPARδ, the receptor undergoes a conformational change that allows it to form a heterodimer with the retinoid X receptor (RXR). This complex then binds to specific DNA sequences called peroxisome proliferator response elements (PPREs) in the promoter regions of target genes.

The downstream transcriptional program activated by this complex includes upregulation of genes encoding enzymes in the fatty acid beta-oxidation pathway, such as carnitine palmitoyltransferase I (CPT-I), which transports long-chain fatty acids into the mitochondria for oxidation. PPARδ activation also increases expression of pyruvate dehydrogenase kinase 4 (PDK4), which inhibits glucose oxidation and effectively pushes cells toward fat as the preferred fuel source. In skeletal muscle, this metabolic shift is associated with the expansion of oxidative, slow-twitch fiber characteristics — which may explain the endurance-related observations seen in animal studies.

In vascular and adipose tissue, PPARδ activation influences reverse cholesterol transport, contributing to the HDL-raising effects observed in animal models. A 2007 review in the American Journal of Cardiology noted that PPARδ regulates multiple steps in lipoprotein metabolism, including modulation of apolipoprotein expression.

In the central nervous system, PPARδ activation appears to suppress inflammatory signaling. A 2009 Journal of Neuroinflammation study found that GW501516 reduced markers of inflammation and demyelination in an in vitro brain inflammation model, and a 2010 Journal of Neuroscience study identified PPARδ regulation of microRNA-15a as a mechanism relevant to protecting cerebrovascular endothelial cells after ischemic injury. These findings suggest PPARδ participates in neuroprotective pathways, though the clinical implications remain unexplored.

It is important to note that the same transcriptional programs that promote fat oxidation and cell survival may also lower barriers to cancer cell proliferation, which is the prevailing mechanistic explanation for the pro-tumorigenic findings observed in animal toxicology studies.

Research into GW-501516 spans metabolic biology, lipid pharmacology, and neuroscience, though the evidence base is anchored almost entirely in animal and cell-based studies. No completed human clinical trial has published results establishing its efficacy or safety for any indication.

A 2006 review in Current Opinion in Investigational Drugs (PMID 16625823) summarized the GlaxoSmithKline and Ligand development program, noting GW-501516's profile as a PPARδ agonist with potential applications in dyslipidemia and the metabolic syndrome. That same year, a study published in the American Journal of Physiology — Endocrinology and Metabolism (PMID 16278250) reported that acute administration of GW-501516 had no immediate effect on glucose transport in isolated skeletal muscle, suggesting its metabolic effects unfold through longer-term gene expression changes rather than rapid signaling.

Lipid biology has been a primary focus. A 2007 supplement to the American Journal of Cardiology (PMID 18047848) reviewed the relationship between PPARδ and lipoproteins, describing how agonist activation of the receptor raises HDL cholesterol and reduces circulating triglycerides in animal models — effects relevant to cardiovascular disease risk reduction. These findings drove the early enthusiasm for GW-501516 as a metabolic drug candidate.

Neurological research has produced intriguing findings. A 2009 Journal of Neuroinflammation study (PMID 19422681) used an in vitro model of brain inflammation and antibody-induced demyelination to show that GW501516 reduced inflammatory markers and protected against myelin damage, effects attributed to PPARβ/δ activation. A 2010 Journal of Neuroscience study (PMID 20445066) found that PPARδ regulates microRNA-15a expression in cerebrovascular endothelial cells following ischemic injury, identifying a previously unknown neuroprotective mechanism. A 2005 Arthritis & Rheumatism study (PMID 15751073) also implicated PPARβ/δ in anti-inflammatory signaling in synovial fibroblasts, suggesting the receptor has broad roles in modulating inflammation.

Chemical analogue research has continued despite the discontinuation of GW-501516 itself. A 2010 European Journal of Medicinal Chemistry paper (PMID 20403648) synthesized triazole analogues of GW 501516 with dual PPARα/δ agonist activity, while a 2010 Archives of Pharmacy study (PMID 21113965) and a 2011 Bioorganic & Medicinal Chemistry paper (PMID 22051054) described fluorine-substituted analogues, exploring how structural modifications affect receptor selectivity and potency. This work reflects ongoing scientific interest in the PPARδ target even as GW-501516 itself has been abandoned.

The critical caveat across this entire body of work is the absence of human efficacy data and the presence of strong preclinical carcinogenicity signals, which define the boundary of what can responsibly be said about this compound's research profile.

No completed human trial has established a dose for GW-501516. Any specific figures circulating online are unverified and not derived from peer-reviewed clinical research. Animal studies have used a range of oral doses, but these cannot be extrapolated to human dosing recommendations.

The safety profile of GW-501516 is defined above all by a serious and reproducible carcinogenicity signal identified during preclinical development. In animal toxicology studies, the compound dramatically accelerated the formation and growth of tumors across multiple organ systems, including the liver, stomach, bladder, skin, and reproductive tissues. Crucially, this occurred at doses and exposure durations consistent with therapeutic use — not at extreme overdose levels. This finding was observed across species and was robust enough that GlaxoSmithKline terminated the clinical development program.

The proposed mechanism behind this toxicity is related to the core biology of PPARδ itself. PPARδ activation promotes cell survival, reduces apoptosis (programmed cell death), and stimulates proliferation — all of which are desirable in healthy muscle tissue but dangerous when applied to pre-cancerous or early-stage cancer cells. A 2006 regulatory review noted this concern explicitly when discussing the compound's development history. The compound may not initiate cancer but may function as a tumor promoter, accelerating the progression of lesions that would otherwise remain dormant.

Beyond oncological risk, the acute tolerability profile in animals was not notably problematic at low doses, and no severe organ toxicity unrelated to tumor promotion has been prominently reported in the peer-reviewed literature at short-term exposures. However, this limited reassurance must be placed against the background of the carcinogenicity data.

No controlled human safety studies have been completed or published. The human safety and side-effect profile of GW-501516 is therefore entirely unknown. Reports circulating in athletic communities are anecdotal, unverified, and cannot be considered scientific evidence. Anti-doping organizations including the World Anti-Doping Agency (WADA) have banned the compound, and regulatory agencies in several countries have issued specific warnings to consumers about products containing GW-501516. The honest summary is that the preclinical safety data gives strong reason for concern, and the absence of human trial data means that concern cannot be resolved in either direction.

GW-501516 is classified as a preclinical compound. GlaxoSmithKline formally discontinued its development program due to preclinical carcinogenicity findings, and no human clinical trials have been completed or published. The compound is not approved in any jurisdiction for any clinical use.

Active research interest has shifted toward GW-501516 as a pharmacological tool for understanding PPARδ biology rather than as a drug candidate. Academic groups have published studies using it to probe PPARδ's role in neuroinflammation, cerebrovascular protection, and lipid metabolism. Chemists have continued to synthesize structural analogues in search of PPARδ modulators with improved safety profiles, as seen in papers published in European and international medicinal chemistry journals between 2010 and 2012.

The PPARδ target itself remains scientifically active, and newer selective agonists are being evaluated in early research for metabolic and inflammatory indications. GW-501516 itself, however, is not currently advancing through any known clinical pipeline. Its continued appearance in the research literature is primarily in the context of mechanistic investigation and as a reference compound for analogue synthesis.